Bart Cornelissen
YOU?
Author Swipe
View article: Surgeons Experience with Head-Mounted Augmented Reality for Intra-articular Fractures in Orthopedic Trauma Surgery
Surgeons Experience with Head-Mounted Augmented Reality for Intra-articular Fractures in Orthopedic Trauma Surgery Open
Conventional 2D imaging in orthopedic trauma surgery lacks depth and requires attention shifts away from the operative field. Head-mounted augmented reality (AR HMDs) may improve intra-operative visualization by overlaying 3D holograms in …
View article: A novel synergistic drug combination of a mitogen-activated extracellular signal-regulated kinase inhibitor with [177Lu]Lu-rhPSMA-10.1 for prostate cancer treatment: Results of a preclinical evaluation
A novel synergistic drug combination of a mitogen-activated extracellular signal-regulated kinase inhibitor with [177Lu]Lu-rhPSMA-10.1 for prostate cancer treatment: Results of a preclinical evaluation Open
The combination of cobimetinib and [177Lu]Lu-rhPSMA-10.1 demonstrated enhanced preclinical therapeutic efficacy versus single agents, supporting clinical investigation of this novel drug combination in prostate cancer.
View article: Correction: Highlight selection of radiochemistry and radiopharmacy developments by editorial board
Correction: Highlight selection of radiochemistry and radiopharmacy developments by editorial board Open
View article: Highlight selection of radiochemistry and radiopharmacy developments by editorial board
Highlight selection of radiochemistry and radiopharmacy developments by editorial board Open
Background The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development and application of radiopharmaceuticals. Main …
View article: Preclinical Evaluation of<sup>177</sup>Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy
Preclinical Evaluation of<sup>177</sup>Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy Open
177Lu-rhPSMA-10.1 is a novel radiohybrid prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy for prostate cancer. We conducted preclinical analyses on non-tumor-bearing BALB/c mice and on prostate canc…
View article: Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapy
Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapy Open
The growing interest and investments in targeted radionuclide therapy (TRT) have expanded research efforts across preclinical and clinical domains. Researchers from diverse fields, including nuclear medicine, radiochemistry, radiopharmacy,…
View article: Molecular Imaging of p53 in Mouse Models of Cancer Using a Radiolabeled Antibody TAT Conjugate with SPECT
Molecular Imaging of p53 in Mouse Models of Cancer Using a Radiolabeled Antibody TAT Conjugate with SPECT Open
Mutations of p53 protein occur in over half of all cancers, with profound effects on tumor biology. We present the first-to our knowledge-method for noninvasive visualization of p53 in tumor tissue in vivo, using SPECT, in 3 different mode…
View article: Issue Information
Issue Information Open
No abstract is available for this article.
View article: [<sup>123</sup>I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer
[<sup>123</sup>I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer Open
Poly(adenosine diphosphate ribose) polymerase (PARP) has emerged as an effective therapeutic strategy against cancer that targets the DNA damage repair enzyme. PARP-targeting compounds radiolabeled with an Auger electron-emitting radionucl…
View article: [15O]H2O PET: Potential or Essential for Molecular Imaging?
[15O]H2O PET: Potential or Essential for Molecular Imaging? Open
Imaging water pathways in the human body provides an excellent way of measuring accurately the blood flow directed to different organs. This makes it a powerful diagnostic tool for a wide range of diseases that are related to perfusion and…
View article: Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy
Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy Open
Auger electron (AE) radiopharmaceutical therapy (RPT) may have the same therapeutic efficacy as α-particles for oncologic small disease, with lower risks of normal-tissue toxicity. The seeds of using AE emitters for RPT were planted severa…
View article: Second Symposium of the European Working Group on the Radiobiology of Molecular Radionuclide Therapy
Second Symposium of the European Working Group on the Radiobiology of Molecular Radionuclide Therapy Open
Molecular radionuclide therapy is a relatively novel anticancer treatment option using radiolabeled, tumor-specific vectors. On binding of these vectors to cancer cells, radioactive decay induces DNA damage and other effects, leading to ca…
View article: Supplementary Methods from Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γH2AX
Supplementary Methods from Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γH2AX Open
PDF - 108KB, Supplementary methods.
View article: Supplementary Methods from Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γH2AX
Supplementary Methods from Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γH2AX Open
PDF - 108KB, Supplementary methods.
View article: Supplementary Figures 1 through 8 from Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γH2AX
Supplementary Figures 1 through 8 from Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γH2AX Open
PDF - 1380KB, Supplementary Figure S1. Schematic overview of the synthesis of (A) non-cleavable anti-gH2AX-PNE and (B) cleavable anti-gH2AX-N-SS-E. Supplementary Figure S2. (A) MDA-MB-468 cultures were exposed to 123I-EGF for 2 h plus incr…
View article: Supplementary Figures 1 through 8 from Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γH2AX
Supplementary Figures 1 through 8 from Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γH2AX Open
PDF - 1380KB, Supplementary Figure S1. Schematic overview of the synthesis of (A) non-cleavable anti-gH2AX-PNE and (B) cleavable anti-gH2AX-N-SS-E. Supplementary Figure S2. (A) MDA-MB-468 cultures were exposed to 123I-EGF for 2 h plus incr…
View article: Data from Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γH2AX
Data from Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γH2AX Open
Many anticancer therapies, including ionizing radiation (IR), cause cytotoxicity through generation of DNA double-strand breaks (DSB). Delivery of therapeutic radionuclides to DNA DSB sites can amplify this DNA damage, for additional thera…
View article: Data from Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γH2AX
Data from Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γH2AX Open
Many anticancer therapies, including ionizing radiation (IR), cause cytotoxicity through generation of DNA double-strand breaks (DSB). Delivery of therapeutic radionuclides to DNA DSB sites can amplify this DNA damage, for additional thera…
View article: Data from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy
Data from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy Open
The tumor suppressor p53 is widely dysregulated in cancer and represents an attractive target for immunotherapy. Because of its intracellular localization, p53 is inaccessible to classical therapeutic monoclonal antibodies, an increasingly…
View article: Supplemental Materials and Methods from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy
Supplemental Materials and Methods from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy Open
Supplemental Materials and Methods from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy
View article: Supplemental Data from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy
Supplemental Data from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy Open
Suppl Table 1: Quantitation of T1-116C binding sites per target cell; Suppl Figure 1: Validation of the HLA-A2/p53RMP tetramer; Suppl Figure 2: ELISA screening of HLA-A2/p53RMP tetramer-reactive TCRm hybridoma supernatants; Suppl Figure 3:…
View article: Data from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy
Data from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy Open
The tumor suppressor p53 is widely dysregulated in cancer and represents an attractive target for immunotherapy. Because of its intracellular localization, p53 is inaccessible to classical therapeutic monoclonal antibodies, an increasingly…
View article: Data from <sup>89</sup>Zr-anti-γH2AX-TAT but not <sup>18</sup>F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma
Data from <sup>89</sup>Zr-anti-γH2AX-TAT but not <sup>18</sup>F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma Open
Purpose: Late-stage, unresectable pancreatic ductal adenocarcinoma (PDAC) is largely resistant to chemotherapy and consequently has a very poor 5-year survival rate of <5%. The ability to assess the efficacy of a treatment soon afte…
View article: Supporting information from <sup>89</sup>Zr-anti-γH2AX-TAT but not <sup>18</sup>F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma
Supporting information from <sup>89</sup>Zr-anti-γH2AX-TAT but not <sup>18</sup>F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma Open
Descriptions of therapeutic regimens, PET/CT image acquisition details, tabulated ex vivo biodistribution data, and results of capecitabine therapy monitoring experiments are provided in the supporting information. TABLE S1: Ex vivo biodis…
View article: Supplemental Data from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy
Supplemental Data from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy Open
Suppl Table 1: Quantitation of T1-116C binding sites per target cell; Suppl Figure 1: Validation of the HLA-A2/p53RMP tetramer; Suppl Figure 2: ELISA screening of HLA-A2/p53RMP tetramer-reactive TCRm hybridoma supernatants; Suppl Figure 3:…
View article: Supplemental Materials and Methods from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy
Supplemental Materials and Methods from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy Open
Supplemental Materials and Methods from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy
View article: Data from <sup>89</sup>Zr-anti-γH2AX-TAT but not <sup>18</sup>F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma
Data from <sup>89</sup>Zr-anti-γH2AX-TAT but not <sup>18</sup>F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma Open
Purpose: Late-stage, unresectable pancreatic ductal adenocarcinoma (PDAC) is largely resistant to chemotherapy and consequently has a very poor 5-year survival rate of <5%. The ability to assess the efficacy of a treatment soon afte…
View article: Supporting information from <sup>89</sup>Zr-anti-γH2AX-TAT but not <sup>18</sup>F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma
Supporting information from <sup>89</sup>Zr-anti-γH2AX-TAT but not <sup>18</sup>F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma Open
Descriptions of therapeutic regimens, PET/CT image acquisition details, tabulated ex vivo biodistribution data, and results of capecitabine therapy monitoring experiments are provided in the supporting information. TABLE S1: Ex vivo biodis…
View article: Supplementary Figure Legends 1-6 from Imaging DNA Damage <i>In Vivo</i> Using γH2AX-Targeted Immunoconjugates
Supplementary Figure Legends 1-6 from Imaging DNA Damage <i>In Vivo</i> Using γH2AX-Targeted Immunoconjugates Open
Supplementary Figure Legends 1-6 from Imaging DNA Damage In Vivo Using γH2AX-Targeted Immunoconjugates
View article: Data from Imaging DNA Damage <i>In Vivo</i> Using γH2AX-Targeted Immunoconjugates
Data from Imaging DNA Damage <i>In Vivo</i> Using γH2AX-Targeted Immunoconjugates Open
DNA damage responses (DDR) occur during oncogenesis and therapeutic responses to DNA damaging cytotoxic drugs. Thus, a real-time method to image DNA damage in vivo would be useful to diagnose cancer and monitor its treatment. Toward…